What are your top takeaways from ASCO GI 2024?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Intermountain Medical Center
Answered on
- ALL CTDNA IS NOT CREATED EQUAL (the only way I reconcile the negative findings of COBRA using a tumor-uninformed assay in predicting the efficacy of adjuvant chemo in stage II colon cancer: https://www.cancernetwork.com/view/ctdna-does-not-confer-chemo-efficacy-in-stage-ii-crc-following-surgery with the findings of BESPOKE https://www.onclive.com/view/ctdna-is-predictive-of-dfs-offers-prognostic-tool-in-crc and GALAXY: https://dailynews.ascopubs.org/do/galaxy-ctdna-negativity-linked-improved-dfs-resectable-colorectal-cancer).
- Rectal cancer management is becoming the most nuanced and inherently multidisciplinary space in GI oncology (not sure anyone says it better than @Dr. First Last: https://x.com/KrishanJethwa/status/1748873240284725478?...
Join for free or sign in to see the full answer